Bette Korber | Academic Influence

Bette Korber's AcademicInfluence.com Rankings

Bette Korber

Computer Science

#3125

World Rank

#3276

Historical Rank

#1242

USA Rank

Database

#1585

World Rank

#1663

Historical Rank

#410

USA Rank

computer-science Degrees

Bette Korber

Biology

#3313

World Rank

#5083

Historical Rank

#1356

USA Rank

Systematics

#31

World Rank

#36

Historical Rank

#11

USA Rank

Bioinformatics

#79

World Rank

#81

Historical Rank

#12

USA Rank

Computational Biology

#123

World Rank

#123

Historical Rank

#31

USA Rank

biology Degrees

Download Badge

Computer Science
Biology

Bette Korber's Degrees

PhD Physics University of California, Berkeley

Why Is Bette Korber Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Bette Korber is an American computational biologist focusing on the molecular biology and population genetics of the HIV virus that causes infection and eventually AIDS. She has contributed heavily to efforts to obtain an effective HIV vaccine. She created a database at Los Alamos National Laboratory that has enabled her to design novel mosaic HIV vaccines, one of which is currently in human testing in Africa. The database contains thousands of HIV genome sequences and related data.

(See a Problem?)

Bette Korber's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus (2020) (3171)
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection (2008) (1911)
Timing the ancestor of the HIV-1 pandemic strains. (2000) (1070)
HIV-1 Nomenclature Proposal (2000) (985)
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus (2013) (940)
A new classification for HIV-1 (1998) (899)
Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA (2004) (858)
Diversity Considerations in HIV-1 Vaccine Selection (2002) (849)
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. (1999) (848)
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection (2009) (781)
Structure of a V3-Containing HIV-1 gp120 Core (2005) (780)
Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies (2004) (757)
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection (2009) (690)
Envelope-Constrained Neutralization-Sensitive HIV-1 After Heterosexual Transmission (2004) (648)
Deciphering Human Immunodeficiency Virus Type 1 Transmission and Early Envelope Diversification by Single-Genome Amplification and Sequencing (2008) (624)
Adaptive Evolution of Human Immunodeficiency Virus-Type 1 During the Natural Course of Infection (1996) (615)
Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies (2009) (610)
Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. (1992) (604)
Evolution and transmission of stable CTL escape mutations in HIV infection (2001) (602)
An African HIV-1 sequence from 1959 and implications for the origin of the epidemic (1998) (600)
HIV sequence compendium 2002 (2002) (544)
Evolutionary and immunological implications of contemporary HIV-1 variation. (2001) (533)
Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG (1995) (513)
Molecular Epidemiology of HIV Transmission in a Dental Practice (1992) (505)
Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2 (2020) (476)
Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. (2004) (468)
Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants (2007) (419)
Human retroviruses and AIDS 1996. A compilation and analysis of nucleic acid and amino acid sequences (1997) (399)
Phenotypic properties of transmitted founder HIV-1 (2013) (389)
Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. (2001) (389)
Genetic and Neutralization Properties of Subtype C Human Immunodeficiency Virus Type 1 Molecular env Clones from Acute and Early Heterosexually Acquired Infections in Southern Africa (2006) (379)
Advantage of rare HLA supertype in HIV disease progression (2003) (372)
Mosaic HIV-1 Vaccines Expand the Breadth and Depth of Cellular Immune Responses in Rhesus Monkeys (2010) (371)
Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G (2016) (355)
Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences (1994) (344)
Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1 (2009) (332)
HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus (2002) (330)
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men (2010) (329)
Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association with Clinical Variables (2009) (326)
Relative Dominance of Gag p24-Specific Cytotoxic T Lymphocytes Is Associated with Human Immunodeficiency Virus Control (2006) (315)
Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys (2013) (312)
Consistent Cytotoxic-T-Lymphocyte Targeting of Immunodominant Regions in Human Immunodeficiency Virus across Multiple Ethnicities (2004) (310)
Human Retroviruses and AIDS. A compilation and analysis of nucleic acid and amino acid sequences: I--II; III--V (1993) (304)
Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection (2014) (302)
Detecting hypermutations in viral sequences with an emphasis on G A hypermutation (2000) (300)
Transmission of Single HIV-1 Genomes and Dynamics of Early Immune Escape Revealed by Ultra-Deep Sequencing (2010) (297)
D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization (2020) (296)
Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses (2018) (292)
Selection for Human Immunodeficiency Virus Type 1 Envelope Glycosylation Variants with Shorter V1-V2 Loop Sequences Occurs during Transmission of Certain Genetic Subtypes and May Impact Viral RNA Levels (2005) (289)
Founder Effects in the Assessment of HIV Polymorphisms and HLA Allele Associations (2007) (279)
Covariation of mutations in the V3 loop of human immunodeficiency virus type 1 envelope protein: an information theoretic analysis. (1993) (275)
Clustering Patterns of Cytotoxic T-Lymphocyte Epitopes in Human Immunodeficiency Virus Type 1 (HIV-1) Proteins Reveal Imprints of Immune Evasion on HIV-1 Global Variation (2002) (271)
Quantitating the Multiplicity of Infection with Human Immunodeficiency Virus Type 1 Subtype C Reveals a Non-Poisson Distribution of Transmitted Variants (2009) (270)
Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA (2005) (267)
Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine (2007) (261)
Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody (2016) (259)
Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies (2014) (259)
Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes (2006) (256)
Broadly targeted CD8+ T cell responses restricted by major histocompatibility complex E (2016) (247)
Signature pattern analysis: a method for assessing viral sequence relatedness. (1992) (244)
Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies (2013) (242)
A computer program designed to screen rapidly for HIV type 1 intersubtype recombinant sequences. (1995) (240)
Quantitative Deep Sequencing Reveals Dynamic HIV-1 Escape and Large Population Shifts during CCR5 Antagonist Therapy In Vivo (2009) (239)
Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes (1996) (236)
Emergence of SARS-CoV-2 through Recombination and Strong Purifying Selection (2020) (228)
Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial (2013) (226)
Genetic and Phenotypic Analyses of Human Immunodeficiency Virus Type 1 Escape from a Small-Molecule CCR5 Inhibitor (2004) (221)
Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines (1998) (220)
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19) (2018) (214)
The emergence of simian/human immunodeficiency viruses. (1992) (213)
Maternal HIV-1 viral load and vertical transmission of infection: The Ariel Project for the prevention of HIV transmission from mother to infant (1997) (209)
Quantitating the Multiplicity of Infection with Human Immunodeficiency Virus Type 1 Subtype C Reveals a Non-Poisson Distribution of Transmitted Variants (2009) (207)
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines (2021) (207)
Antigenicity and Immunogenicity of a Synthetic Human Immunodeficiency Virus Type 1 Group M Consensus Envelope Glycoprotein (2005) (205)
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination (2022) (202)
Identification of human immunodeficiency virus type 1 envelope genes recombinant between subtypes B and F in two epidemiologically linked individuals from Brazil (1994) (200)
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. (2012) (200)
A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. (2006) (197)
Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS (1997) (196)
Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. (2012) (192)
HIV Evolution in Early Infection: Selection Pressures, Patterns of Insertion and Deletion, and the Impact of APOBEC (2009) (192)
Evidence of Differential HLA Class I-Mediated Viral Evolution in Functional and Accessory/Regulatory Genes of HIV-1 (2007) (192)
Early Low-Titer Neutralizing Antibodies Impede HIV-1 Replication and Select for Virus Escape (2012) (188)
HIV-1 Evolution and Disease Progression (1996) (185)
Immunoinformatics Comes of Age (2006) (184)
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines (2021) (184)
Lack of strong immune selection pressure by the immunodominant, HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection. (1998) (180)
The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1--a meta-analysis of 15 prospective cohort studies. (1999) (177)
Immune control of HIV: the obstacles of HLA and viral diversity (2001) (176)
Staged induction of HIV-1 glycan–dependent broadly neutralizing antibodies (2017) (176)
Modeling sequence evolution in acute HIV-1 infection. (2009) (175)
Impact of HLA-B Alleles, Epitope Binding Affinity, Functional Avidity, and Viral Coinfection on the Immunodominance of Virus-Specific CTL Responses1 (2006) (174)
Human immunodeficiency virus type 1 genetic evolution in children with different rates of development of disease (1997) (173)
Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial (2013) (173)
Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351 (2021) (172)
SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse (2021) (168)
HIV sequence databases. (2003) (167)
Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development (1997) (165)
Mosaic Vaccines Elicit CD8+ T lymphocyte Responses in Monkeys that Confer Enhanced Immune Coverage of Diverse HIV Strains (2010) (163)
Genetic and Functional Analysis of Full-Length Human Immunodeficiency Virus Type 1 env Genes Derived from Brain and Blood of Patients with AIDS (2003) (160)
Emergence of SARS-CoV-2 through recombination and strong purifying selection (2020) (157)
Definition of the viral targets of protective HIV-1-specific T cell responses (2011) (157)
Fitness Costs and Diversity of the Cytotoxic T Lymphocyte (CTL) Response Determine the Rate of CTL Escape during Acute and Chronic Phases of HIV Infection (2011) (156)
HLA Class I-Driven Evolution of Human Immunodeficiency Virus Type 1 Subtype C Proteome: Immune Escape and Viral Load (2008) (153)
Quantifying the Diversification of Hepatitis C Virus (HCV) during Primary Infection: Estimates of the In Vivo Mutation Rate (2012) (152)
jpHMM: Improving the reliability of recombination prediction in HIV-1 (2009) (152)
A Polymorphism in the Regulatory Region of the CC-Chemokine Receptor 5 Gene Influences Perinatal Transmission of Human Immunodeficiency Virus Type 1 to African-American Infants (1999) (151)
Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection (2018) (148)
Enhanced Detection of Human Immunodeficiency Virus Type 1-Specific T-Cell Responses to Highly Variable Regions by Using Peptides Based on Autologous Virus Sequences (2003) (147)
Human retroviruses and AIDS 1997 (1997) (146)
Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1 (1994) (145)
T-Cell Vaccine Strategies for Human Immunodeficiency Virus, the Virus with a Thousand Faces (2009) (144)
Immunological and Virological Mechanisms of Vaccine-Mediated Protection Against SIV and HIV (2013) (143)
Recurrent Signature Patterns in HIV-1 B Clade Envelope Glycoproteins Associated with either Early or Chronic Infections (2011) (139)
Diversity of V3 region sequences of human immunodeficiency viruses type 1 from the central African Republic. (1993) (139)
Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection (2016) (136)
A Sound Rationale Needed for Phase III HIV-1 Vaccine Trials (2004) (133)
Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques (2015) (133)
Variability of human immunodeficiency virus type 1 group O strains isolated from Cameroonian patients living in France (1995) (132)
HIV-Host Interactions: Implications for Vaccine Design. (2016) (129)
HIV-1 Nef is preferentially recognized by CD8 T cells in primary HIV-1 infection despite a relatively high degree of genetic diversity (2004) (128)
Maintaining the integrity of human immunodeficiency virus sequence databases (1996) (128)
Extensive HLA class I allele promiscuity among viral CTL epitopes (2007) (127)
Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies (2001) (125)
The Ariel Project: A prospective cohort study of maternal-child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy. (1999) (125)
A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B (1995) (124)
Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity (2021) (121)
The role of recombination in the emergence of a complex and dynamic HIV epidemic (2010) (120)
Comparison of Viral Env Proteins from Acute and Chronic Infections with Subtype C Human Immunodeficiency Virus Type 1 Identifies Differences in Glycosylation and CCR5 Utilization and Suggests a New Strategy for Immunogen Design (2013) (119)
Role of donor genital tract HIV-1 diversity in the transmission bottleneck (2011) (118)
Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes (2014) (117)
Numbering Positions in HIV Relative to HXB 2 CG (1999) (117)
HIV-1 Subtype and Circulating Recombinant Form (CRF) Reference Sequences, 2005 (2005) (115)
Polymerase chain reaction analysis of defective human T-cell leukemia virus type I proviral genomes in leukemic cells of patients with adult T-cell leukemia (1991) (114)
Characterization of Novel Simian Immunodeficiency Viruses from Red-Capped Mangabeys from Nigeria (SIVrcmNG409 and -NG411) (2001) (113)
Relationship between Functional Profile of HIV-1 Specific CD8 T Cells and Epitope Variability with the Selection of Escape Mutants in Acute HIV-1 Infection (2011) (113)
HIV-1 nomenclature proposal: a reference guide to HIV-1 classification. (2000) (112)
HIV-1 vaccine development after STEP. (2010) (112)
Human retroviruses and aids, 1992 (1992) (111)
Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge (2017) (111)
The SARS-CoV-2 Spike Variant D614G Favors an Open Conformational State (2020) (110)
Regulation of gene expression by interferons: control of H-2 promoter responses. (1988) (109)
Role of Maternal Autologous Neutralizing Antibody in Selective Perinatal Transmission of Human Immunodeficiency Virus Type 1 Escape Variants (2006) (108)
Large-scale amplification, cloning and sequencing of near full-length HIV-1 subtype C genomes. (2006) (107)
Ancestral and consensus envelope immunogens for HIV-1 subtype C. (2006) (106)
Human leukocyte antigen–associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution (2007) (106)
Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail (2017) (105)
Potent and broad HIV-neutralizing antibodies in memory B cells and plasma (2017) (101)
Unique Mutational Patterns in the Envelope α2 Amphipathic Helix and Acquisition of Length in gp120 Hypervariable Domains Are Associated with Resistance to Autologous Neutralization of Subtype C Human Immunodeficiency Virus Type 1 (2007) (101)
A jumping profile Hidden Markov Model and applications to recombination sites in HIV and HCV genomes (2006) (98)
CATNAP: a tool to compile, analyze and tally neutralizing antibody panels (2015) (96)
Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection. (2016) (94)
The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. (2004) (93)
Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. (2009) (93)
Antigenicity and Immunogenicity of Transmitted/Founder, Consensus, and Chronic Envelope Glycoproteins of Human Immunodeficiency Virus Type 1 (2013) (90)
Estimating time since infection in early homogeneous HIV-1 samples using a poisson model (2010) (90)
Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge (2017) (90)
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. (1998) (89)
Elucidation of Hepatitis C Virus Transmission and Early Diversification by Single Genome Sequencing (2012) (87)
Association between maternal and infant class I and II HLA alleles and of their concordance with the risk of perinatal HIV type 1 transmission. (2002) (87)
Frequent Detection of Escape from Cytotoxic T-Lymphocyte Recognition in Perinatal Human Immunodeficiency Virus (HIV) Type 1 Transmission: the Ariel Project for the Prevention of Transmission of HIV from Mother to Infant (1999) (86)
Genetic Signatures in the Envelope Glycoproteins of HIV-1 that Associate with Broadly Neutralizing Antibodies (2010) (86)
Limitations of a molecular clock applied to considerations of the origin of HIV-1. (1998) (84)
Epitope Escape Mutation and Decay of Human Immunodeficiency Virus Type 1-Specific CTL Responses 1 (2003) (84)
HLA-B63 Presents HLA-B57/B58-Restricted Cytotoxic T-Lymphocyte Epitopes and Is Associated with Low Human Immunodeficiency Virus Load (2005) (83)
Retrieval and on-the-fly alignment of sequence fragments from the HIV database (2001) (83)
HIV Sequence Compendium 2010 (2010) (82)
Proteome-wide analysis of HIV-specific naive and memory CD4+ T cells in unexposed blood donors (2014) (82)
Mycobacterium tuberculosis--heterogeneity revealed through whole genome sequencing. (2012) (82)
The SARS-CoV-2 Spike variant D614G favors an open conformational state (2021) (82)
A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys (2008) (81)
Using human immunodeficiency virus type 1 sequences to infer historical features of the acquired immune deficiency syndrome epidemic and human immunodeficiency virus evolution. (2001) (80)
Los Alamos Hepatitis C Immunology Database (2005) (79)
Multiple lineages of Monkeypox virus detected in the United States, 2021- 2022 (2022) (79)
Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth (2018) (78)
Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization (2016) (78)
Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. (2007) (78)
Targeting of a CD8 T cell env epitope presented by HLA-B*5802 is associated with markers of HIV disease progression and lack of selection pressure. (2008) (77)
Impact of Clade, Geography, and Age of the Epidemic on HIV-1 Neutralization by Antibodies (2014) (75)
Clade-Specific Differences between Human Immunodeficiency Virus Type 1 Clades B and C: Diversity and Correlations in C3-V4 Regions of gp120 (2007) (75)
Extensive Intrasubtype Recombination in South African Human Immunodeficiency Virus Type 1 Subtype C Infections (2007) (74)
Fitness costs of rifampicin resistance in Mycobacterium tuberculosis are amplified under conditions of nutrient starvation and compensated by mutation in the β′ subunit of RNA polymerase (2014) (74)
Heterogeneity of HIV-1 and HIV-2. (1995) (74)
HIV Sequence Compendium 2018 (2018) (74)
Expanded Breadth of the T-Cell Response to Mosaic Human Immunodeficiency Virus Type 1 Envelope DNA Vaccination (2008) (72)
HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design (2019) (72)
Regulation of murine class I genes by interferons is controlled by regions located both 5' and 3' to the transcription initiation site. (1987) (70)
Genetic evaluation of suspected cases of transient HIV-1 infection of infants. (1998) (70)
Consistent Patterns of Change during the Divergence of Human Immunodeficiency Virus Type 1 Envelope from That of the Inoculated Virus in Simian/Human Immunodeficiency Virus-Infected Macaques (2006) (70)
Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection (2018) (70)
Cross-Subtype T-Cell Immune Responses Induced by a Human Immunodeficiency Virus Type 1 Group M Consensus Env Immunogen (2006) (69)
Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents (2002) (69)
Mapping HIV-1 Vaccine Induced T-Cell Responses: Bias towards Less-Conserved Regions and Potential Impact on Vaccine Efficacy in the Step Study (2011) (68)
Structural diversity of the SARS-CoV-2 Omicron spike (2022) (68)
Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization (2021) (66)
Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections (2018) (65)
Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. (2015) (65)
Protecting HIV databases (1995) (63)
A Signature in HIV-1 Envelope Leader Peptide Associated with Transition from Acute to Chronic Infection Impacts Envelope Processing and Infectivity (2011) (63)
A Mechanistic Understanding of Allosteric Immune Escape Pathways in the HIV-1 Envelope Glycoprotein (2013) (62)
jpHMM at GOBICS: a web server to detect genomic recombinations in HIV-1 (2006) (62)
Detection of HIV-1 p24 Gag in plasma by a nanoparticle-based bio-barcode-amplification method. (2008) (62)
Evolution of hepatitis C viral quasispecies after liver transplantation. (2001) (61)
Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity (2004) (61)
The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility (2009) (60)
Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron Escape from Neutralizing Antibodies (2021) (59)
Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. (2017) (59)
Defining the risk of SARS-CoV-2 variants on immune protection (2022) (58)
Characterization and Comparison of Recombinant Simian Immunodeficiency Virus from Drill (Mandrillus leucophaeus) and Mandrill (Mandrillus sphinx) Isolates (2003) (57)
The KIR and CD94/NKG2 families of molecules in the rhesus monkey (2001) (54)
Standard conditions of virus isolation reveal biological variability of HIV type 1 in different regions of the world. WHO Network for HIV Isolation and Characterization. (1994) (54)
Defining the HLA class I‐associated viral antigen repertoire from HIV‐1‐infected human cells (2015) (54)
Maternal viral load and rate of disease progression among vertically HIV-1-infected children: an international meta-analysis (2003) (52)
The TRIM5 Gene Modulates Penile Mucosal Acquisition of Simian Immunodeficiency Virus in Rhesus Monkeys (2011) (51)
The World Health Organization Global Programme on AIDS Proposal for Standardization of HIV Sequence Nomenclature (1994) (51)
Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens. (2012) (50)
Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. (2020) (47)
Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection (2017) (47)
Full-Length HIV-1 Immunogens Induce Greater Magnitude and Comparable Breadth of T Lymphocyte Responses to Conserved HIV-1 Regions Compared with Conserved-Region-Only HIV-1 Immunogens in Rhesus Monkeys (2012) (46)
Construction and Evaluation of Novel Rhesus Monkey Adenovirus Vaccine Vectors (2014) (46)
HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens (2021) (45)
Web-based design and evaluation of T-cell vaccine candidates (2008) (45)
Cross-reactive CD8+ T cell epitopes identified in US adolescent minorities. (2003) (44)
Polyvalent vaccine approaches to combat HIV‐1 diversity (2017) (44)
Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates (2015) (44)
Coping with Viral Diversity in HIV Vaccine Design: A Response to Nickle et al (2008) (43)
Influence of HLA Alleles on the Rate of Progression of Vertically Transmitted HIV Infection in Children: Association of Several HLA-DR13 Alleles with Long-Term Survivorship and the Potential Association of HLA-A2301 with Rapid Progression to AIDS (1997) (43)
Erratum: HIV-1 superinfection despite broad CD8 + T-cell responses containing replication of the primary virus (Nature (2002) 420 (434-439)) (2003) (43)
Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies (2019) (43)
A multiple-alignment based primer design algorithm for genetically highly variable DNA targets (2013) (43)
Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody (2018) (42)
Partial Protection of Simian Immunodeficiency Virus (SIV)-Infected Rhesus Monkeys against Superinfection with a Heterologous SIV Isolate (2009) (41)
Epitope-Specific CD8+ T Lymphocytes Cross-Recognize Mutant Simian Immunodeficiency Virus (SIV) Sequences but Fail To Contain Very Early Evolution and Eventual Fixation of Epitope Escape Mutations during SIV Infection (2011) (41)
Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates. (2006) (40)
A Multivalent Clade C HIV-1 Env Trimer Cocktail Elicits a Higher Magnitude of Neutralizing Antibodies than Any Individual Component (2014) (39)
HIV Sequence Sigmatires and Similarities (2002) (39)
HIV Sequence Compendium 2015 (2015) (38)
Structural diversity of the SARS-CoV-2 Omicron spike (2022) (38)
Autologous Neutralizing Antibodies to the Transmitted/Founder Viruses Emerge Late after Simian Immunodeficiency Virus SIVmac251 Infection of Rhesus Monkeys (2010) (38)
Increased detection of HIV-specific T cell responses by combination of central sequences with comparable immunogenicity (2008) (37)
Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost (2015) (37)
Increased Sequence Diversity Coverage Improves Detection of HIV-Specific T Cell Responses1 (2007) (37)
Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth (2020) (37)
HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees (2018) (36)
Updated proposal of reference sequences for the HIV-1 genetic subtypes. (1997) (36)
Quantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine development. (2015) (36)
Identification of a novel clade of human immunodeficiency virus type 1 in Democratic Republic of Congo. (2002) (35)
Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity. (2010) (35)
HIV-1 intrapatient sequence diversity in the immunogenic V3 region. (1991) (35)
Increased Valency of Conserved-mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition. (2016) (34)
Killer cell immunoglobulin‐like receptors (KIR) of the African‐origin sabaeus monkey: evidence for recombination events in the evolution of KIR (2005) (34)
Genetic Characterization of Diverse HIV-1 Strains in an Immigrant Population Living in New York City (2006) (34)
Distinct Evolutionary Pressures Underlie Diversity in Simian Immunodeficiency Virus and Human Immunodeficiency Virus Lineages (2012) (33)
HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design (2019) (33)
Human retroviruses and AIDS, 1991. [CONTAINS GLOSSARY] (1991) (32)
Associations between amino acids in the evolution of HIV type 1 protease sequences under indinavir therapy. (1999) (31)
Characterization and Immunogenicity of a Novel Mosaic M HIV-1 gp140 Trimer (2014) (31)
Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins. (2009) (31)
Liver transplantation with hepatitis C virus‐infected graft: Interaction between donor and recipient viral strains (2003) (30)
HIV-1 sequence variation between isolates from mother-infant transmission pairs. (1992) (29)
Epigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus Vaccine (2016) (29)
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector (2018) (29)
Influence of HLA alleles on the rate of progression of vertically transmitted HIV infection in children: association of several HLA-DR13 alleles with long-term survivorship and the potential association of HLA-A*2301 with rapid progression to AIDS. Long-Term Survivor Study. (1997) (28)
Epitopes Immediately below the Base of the V3 Loop of gp120 as Targets for the Initial Autologous Neutralizing Antibody Response in Two HIV-1 Subtype B-Infected Individuals (2011) (28)
Recombination-mediated escape from primary CD8+ T cells in acute HIV-1 infection (2014) (26)
Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations (2019) (26)
T cell-based strategies for HIV-1 vaccines (2019) (26)
Centralized HIV-1 envelope immunogens and neutralizing antibodies. (2007) (25)
HIV Molecular Immunology 2001 (2001) (24)
Designing and Testing Broadly-Protective Filoviral Vaccines Optimized for Cytotoxic T-Lymphocyte Epitope Coverage (2012) (24)
T cell responses in HIV type 1-infected adolescent minorities share similar epitope specificities with whites despite significant differences in HLA class I alleles. (2003) (24)
Structure and Function of CC-Chemokine Receptor 5 Homologues Derived from Representative Primate Species and Subspecies of the Taxonomic Suborders Prosimii and Anthropoidea (2003) (24)
Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120. (2011) (24)
Longitudinal and cross-sectional analysis of cytotoxic T lymphocyte responses and their relationship to vertical human immunodeficiency virus transmission. ARIEL Project Investigators. (1998) (24)
Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants (2015) (23)
Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments (2017) (23)
A Multi-Component Prime-Boost Vaccination Regimen with a Consensus MOMP Antigen Enhances Chlamydia trachomatis Clearance (2016) (22)
Approaches to the development of broadly protective HIV vaccines: challenges posed by the genetic, biological and antigenic variability of HIV-1: Report* from a meeting of the WHO-UNAIDS Vaccine Advisory Committee** Geneva, 21–23 February 2000 (2001) (22)
The evolutionary rate dynamically tracks changes in HIV-1 epidemics: application of a simple method for optimizing the evolutionary rate in phylogenetic trees with longitudinal data. (2009) (22)
Effective Cytotoxic T Lymphocyte Targeting of Persistent HIV-1 during Antiretroviral Therapy Requires Priming of Naive CD8+ T Cells (2016) (21)
Detection of interleukin 10 in cerebrospinal fluid of patients with subacute sclerosing panencephalitis (2005) (21)
HIV-1 intra-subtype superinfection rates: estimates using a structured coalescent with recombination. (2005) (21)
Genital Tract Sequestration of SIV following Acute Infection (2011) (21)
The sequential introduction of HIV-1 subtype B and CRF01AE in Singapore by sexual transmission: accelerated V3 region evolution in a subpopulation of Asian CRF01 viruses. (2002) (20)
HIV type 1 V3 region primer-induced antibody suppression is overcome by administration of C4-V3 peptides as a polyvalent immunogen. (1995) (19)
HIV type 1 molecular clones able to use the Bonzo/STRL-33 coreceptor for virus entry. (2001) (19)
Histidine 375 Modulates CD4 Binding in HIV-1 CRF01_AE Envelope Glycoproteins (2016) (18)
A computational framework for the analysis of peptide microarray antibody binding data with application to HIV vaccine profiling. (2013) (18)
Alternative effector-function profiling identifies broad HIV-specific T-cell responses in highly HIV-exposed individuals who remain uninfected. (2015) (18)
Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1 (2023) (18)
Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models (2013) (17)
Converging on an HIV Vaccine (2011) (17)
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial (2021) (17)
Antigenicity-defined conformations of an extremely neutralization-resistant HIV-1 envelope spike (2017) (17)
Molecular characterization of a highly divergent HIV type 1 isolate obtained early in the AIDS epidemic from the Democratic Republic of Congo. (2001) (17)
Correction: Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies (2019) (17)
Hepatitis C Genotype 1 Mosaic Vaccines Are Immunogenic in Mice and Induce Stronger T-Cell Responses than Natural Strains (2012) (16)
Effect of Glycosylation on an Immunodominant Region in the V1V2 Variable Domain of the HIV-1 Envelope gp120 Protein (2016) (16)
Exploring the Role of Glycans in the Interaction of SARS-CoV-2 RBD and Human Receptor ACE2 (2021) (16)
Fitness costs and diversity of CTL response determine the rate of CTL escape during the acute and chronic phases of HIV infection (105.23) (2011) (15)
Complete protection of the BALB/c and C57BL/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epigraph vaccine (2019) (15)
The World Health Organization Global Programme on AIDS proposal for standardization of HIV sequence nomenclature. WHO Network for HIV Isolation and Characterization. (1994) (15)
HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies. (2017) (14)
The spread of HIV in Africa. (2005) (14)
Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies (2022) (14)
Hitting the sweet spot: exploiting HIV-1 glycan shield for induction of broadly neutralizing antibodies. (2020) (14)
Quantification of the Resilience and Vulnerability of HIV-1 Native Glycan Shield at Atomistic Detail (2019) (14)
Graph‐based optimization of epitope coverage for vaccine antigen design (2017) (13)
A single, continuous metric to define tiered serum neutralization potency against HIV (2018) (13)
Response: HIV-1 Evolution and Disease Progression (1996) (13)
Unusual pattern of antibodies to human T-cell leukemia virus type-I in family members of adult T-cell leukemia patients (1991) (13)
HIV‐1 Reverse Transcriptase: A Diversity Generator and Quasispecies Regulator (1993) (13)
Characterization of the SARS-CoV-2 B.1.621 (Mu) variant (2022) (12)
Substantial Neutralization Escape by the SARS-CoV-2 Omicron Variant BQ.1.1 (2022) (12)
Numbering Positions in SIV Relative to SIVMM 239 (2005) (12)
Rare HLA drive additional HIV evolution compared to more frequent alleles. (2009) (12)
Survey of British clinicians' views on management of patients in persistent vegetative state (1996) (12)
PeptGen: Designing Peptides for Immunological Studies and Application to HIV Consensus Sequences (2000) (11)
Mother-to-child transmission in the United States of subtypes D and A/G human immunodeficiency virus type 1. (2002) (11)
Envelope Vaccination Shapes Viral Envelope Evolution following Simian Immunodeficiency Virus Infection in Rhesus Monkeys (2009) (11)
Covariation of Mutations in the V3 Loop of HIV-1: An Information Theoretic Analysis (1995) (11)
HIV Molecular Immunology 2014 (2015) (10)
HIV classification using the coalescent theory (2010) (10)
Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial (2022) (10)
Epigraph hemagglutinin vaccine induces broad cross-reactive immunity against swine H3 influenza virus (2020) (10)
Correction: Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine (2011) (10)
Longitudinal and Cross-Sectional Analysis of Cytotoxic T Lymphocyte Responses and Their Relationship to Vertical Human Immunodeficiency Virus Transmission (1998) (9)
Tetravalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth (2020) (9)
Epidemiological and Immunological Implications of the Global Variability of HIV-1 (2001) (9)
HIV Molecular Immunology 2015 (2016) (9)
Viral genome analysis and knowledge management. (2013) (8)
Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters (2023) (8)
mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice (2022) (8)
Modeling sequence evolution in HIV-1 infection with recombination. (2013) (8)
Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition (2022) (8)
Partial protection of SIV-infected rhesus monkeys against superinfection with a heterologous SIV isolate (2009) (8)
Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates (2022) (8)
Recent Evolutionary History of Human Immunodeficiency Virus Type 1 Subtype B—Response (2003) (7)
Dendritic cells focus CTL responses toward highly conserved and topologically important HIV epitopes (2020) (7)
Corrigendum to “Modeling sequence evolution in acute HIV-1 infection” [J. Theor. Biol. 261 (2009) 341–360] (2012) (7)
Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens (2021) (6)
Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates (2018) (6)
TRIM5 modulates penile mucosal acquisition of simian immunodeficiency virus in rhesus monkeys (2011) (6)
Unusual pattern of antibodies to human T-cell leukemia virus type-I in family members of adult T-cell leukemia patients. (1991) (6)
Vaccine-Induced CD8+ T Lymphocytes of Rhesus Monkeys Recognize Variant Forms of an HIV Epitope but Do Not Mediate Optimal Functional Activity (2011) (6)
addendum: HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus (2003) (5)
Integrated sequence and immunology filovirus database at Los Alamos (2016) (5)
Estimating the Timing of Early Simian-Human Immunodeficiency Virus Infections: a Comparison between Poisson Fitter and BEAST (2020) (5)
A Plea for Justice for Jailed Medical Workers (2006) (5)
Mycobacterium tuberculosis e Heterogeneity revealed through whole genome sequencing (2012) (5)
Erratum for Smith et al., Effective Cytotoxic T Lymphocyte Targeting of Persistent HIV-1 during Antiretroviral Therapy Requires Priming of Naive CD8+ T Cells (2016) (5)
P09-21 LB. Deep sequencing of HIV-1 from acute infection: low initial diversity, and rapid but variable CTL escape (2009) (4)
Recombination and low-diversity confound homoplasy-based methods to detect the effect of SARS-CoV-2 mutations on viral transmissibility (2021) (4)
replication of the primary virus (2002) (4)
Capturing viral diversity for in-vitro test reagents and HIV vaccine immunogen design (2007) (4)
Effect of epitope variant co-delivery on the depth of CD8 T cell responses induced by HIV-1 conserved mosaic vaccines (2021) (4)
Correction for Hraber et al., “Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments” (2018) (3)
Current methods for diagnosis of human tuberculosis and considerations for global surveillance. (2015) (3)
Development of a Universal T Cell Vaccine (2008) (3)
Evaluation of different V3 peptides in an enzyme immunoassay for specific HIV type 1 group O antibody detection. (1998) (3)
Comment to the Letter to the Editor (1998) (3)
Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection. (2014) (3)
Longitudinal and Cross-Sectional Analysis of Cytotoxic T Lymphocyte (CTL) Responses and their Relationship to Vertical HIV Transmission (1998) (3)
P16-24. Crucial contribution of sub-dominant HLA-C allele restricted CTL responses to the control of HIV (2009) (3)
Dating the origin of HIV-I subtypes - reply (1999) (3)
Correction: Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection (2017) (3)
Building on the past to define an efficient path to an HIV vaccine (2011) (3)
Contrasting HIV phylogenetic relationships and V3 loop protein similarities (1992) (3)
Regulatory Elements in the Promoter of the H-2Dd Class I Gene (1987) (3)
Expression and evolutionary analysis of West Nile virus (Merion Strain) (2005) (3)
HLA and HIV Infection Progression: Application of the Minimum Description Length Principle to Statistical Genetics (2005) (2)
Research on infectious disease dynamics. Introduction. (2009) (2)
jpHMM: improving the reliability of recombination prediction in HIV-1 (2010) (2)
Correction: Evidence of Differential HLA Class I-Mediated Viral Evolution in Functional and Accessory/Regulatory Genes of HIV-1 (2007) (2)
Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations (2019) (2)
Genetic and Phenotypic Analyses of Human Immunodeficiency Virus Type 1 Escape from a Small-Molecule CCR5 Inhibitor (2004) (2)
Analyses of inter- and intra-patient variation in the V3 loop of the HIV-1 envelope protein (1991) (2)
for the origin of the epidemic (1998) (1)
Using human immunode ciency virus type 1 sequences to infer historical features of the acquired immune de ciency syndrome epidemic and human immunode ciency virus evolution (2004) (1)
116 Autologous and Heterologous Neutralizing Antibody Responses in HIV-1 Infection (2012) (1)
Germline-targeting and Reverse Engineering to Elicit CH235.12 Lineage bNAbs (2018) (1)
Association of HLA class I supertypes with HIV-1 disease progression in the Chicago MACS: evidence for frequency-dependent selection (2002) (1)
P19-01. Pre-clinical immunogenicity of mosaic Asian AE/B HIV-1 DNA vaccine in mice (2009) (1)
Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization (2017) (1)
Recombination-mediated escape from primary CD8+ T cells in acute HIV-1 infection (2014) (1)
Partial Protection of Simian Immunodeficiency Virus (SIV)-Infected Rhesus Monkeys against Superinfection with a Heterologous SIV Isolate (2009) (1)
HLA-restricted immune responses have driven the evolution of HIV-1 clades (2005) (1)
Extensive HLA class I binding promiscuity among EBV- and HIV- derived cytotoxic T lymphocyte epitopes (2004) (1)
Identi fi cation of amino acid substitutions associated with neutralization phenotype in the human immunode fi ciency virus type-1 subtype C gp 120 (2016) (1)
Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial (2021) (1)
A multiple-alignment based primer design algorithm for genetically highly variable DNA targets (2013) (1)
SARS-CoV-2 variant transition dynamics are associated with vaccination rates, number of co-circulating variants, and convalescent immunity (2023) (1)
A Network-based approach for Quantifying the Resilience and Vulnerability of HIV-1 Native Glycan Shield (2019) (1)
Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models (2013) (1)
AIDS Vaccine 2003. 18-21 September 2003, New York, NY, USA. (2003) (1)
Sequence Quality Control Sequence Quality Control (1999) (1)
Clade-Speciﬁc Differences between Human Immunodeﬁciency Virus Type 1 Clades B and C: Diversity and Correlations in C3-V4 Regions of gp120 (cid:1) (2007) (0)
Rapid selection of escape mutants by the first CD8 T cell responses in acute HIV-1 infection (2008) (0)
Development of Pan-filovirus vaccine against Ebola and Marburg virus challenges (2018) (0)
Brian Gaschen , Diversity Considerations in HIV-1 Vaccine Selection (2009) (0)
Polymorphisms and HLA Allele Associations Founder Effects in the Assessment of HIV (2008) (0)
Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates (2021) (0)
P04-54 LB. Genetic signature analysis identifies the CD4i region of gp120 as a determinant of broadly NAb responses in HIV-1-infected individuals (2009) (0)
The Role of T Cell Immunity in the Control of HIV Infection (2010) (0)
Compensatory mutation in RpoC restores fitness to rifampicin-resistant multi-drug resistant Mycobacterium tuberculosis. (2012) (0)
SARS-CoV-2 variant transition dynamics are associated with vaccination rates, number of co-circulating variants, and natural immunity (2022) (0)
Emerging pathogens: Dynamics, mutation and drug resistance (1997) (0)
A Germline-Targeting Chimpanzee SIV Envelope Glycoprotein Elicits a New Class of V2-Apex Directed Cross-Neutralizing Antibodies (2022) (0)
Emergence of recombinant forms in geographic regions with co-circulating HIV subtypes in the dynamic HIV-1 epidemic (2009) (0)
Expanded breadth of the T-cell response to mosaic HIV-1 envelope DNA vaccination (2009) (0)
Identification of full-length transmitted/founder viruses and their progeny in primary HIV-1 infection (2009) (0)
P04-41. Kinetics of antibody neutralization and viral evolution following envelope vaccination in SIV-infected rhesus monkeys (2009) (0)
Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection (2018) (0)
Recombinant gp 120 Subunit Vaccines Virus Type 1 while Participating in Trials of Persons Infected by Human Immunodeficiency Immunological and Virological Analyses of (1998) (0)
LANL/New Mexico Consortium HIV vaccine design and Analysis (2014) (0)
Time is of the essence , yet human efficacy trials by their fundamental nature take years to complete ... Combining improved B-cell and T-cell strategies may be the most efficient route forward . ” (2009) (0)
Crystal structure of HIV-1 JR-FL gp120 core protein containing the third variable region (V3) complexed with CD4 and the X5 antibody (2005) (0)
Author Correction: Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies (2023) (0)
Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex (2022) (0)
African-American Infants Human Immunodeficiency Virus Type 1 to Influences Perinatal Transmission of of the CC-Chemokine Receptor 5 Gene A Polymorphism in the Regulatory Region (2013) (0)
Network Analysis of the Communication Pathways in HIV-1 Envelope Proteins For Mechanistic Understanding of Immune Escape (2011) (0)
P.191 HLA-associated sequence polymorphisms in HCV reveal the reproducibility of immune responses and constraints on viral evolution (2006) (0)
Network analysis uncovers the communication structure of SARS-CoV-2 spike protein identifying sites for immunogen design (2022) (0)
Regulation of class I genes by interferons (1988) (0)
Positive‐strand RNA viruses—a Keystone Symposia report (2023) (0)
Comparison of the depth of vaccine-elicited HIV-1 Env epitope-specific CD8+ T lymphocyte responses (2012) (0)
StrainsT-Cell Responses than Natural Are Immunogenic in Mice and Induce Hepatitis C Genotype 1 Mosaic Vaccines (2014) (0)
Network analysis outlines strengths and weaknesses of emerging SARS-CoV-2 Spike variants (2021) (0)
Stability and neutralization capacity of a novel mosaic HIV-1 gp140 trimer in a guinea pig model (2012) (0)
C106 Distinguishing Features of Transmitted/Founder HIV-1 (2013) (0)
Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults (2023) (0)
The HIV Databases: History, Design and Function (2002) (0)
Peptide microarrays for coverage of sequence diversity in monitoring the B cell immune response (TECH2P.911) (2015) (0)
OA06-04. The role of early T-cell responses in subjects with acute HIV-1 infection (2009) (0)
P16-42. Characterisation of HIV-1 specific T-cell responses in exposed uninfected individuals from a London cohort (2009) (0)
WHO-UNAIDS Guidelines for Standard HIV Isolation and Characterisation Procedures. (2002) (0)
Full-length HIV-1 immunogens induce greater T lymphocyte responses to conserved epitopes than conserved-region-only HIV-1 immunogens in monkeys (2012) (0)
Impact of mutations near the SARS-CoV-2 furin-cleavage site on viral infectivity (2022) (0)
P.337 Rational design of HCV vaccine cocktails that maximize coverage of potential CTL epitopes (2006) (0)
Candidate mosaic proteins for a pan-filoviral cytotoxic T-Cell lymphocyte vaccine (2008) (0)
US National Institutes of Health Prioritization of SARS-CoV-2 Variants (2023) (0)
Full-length HIV-1 immunogens induce greater T lymphocyte responses to conserved epitopes than conserved-region-only HIV-1 immunogens in monkeys (2012) (0)
Talk: Why Vaccines? (2014) (0)
Improves Detection of HIV-Specific T Cell Increased Sequence Diversity Coverage (2007) (0)
Strategy for Immunogen Design CCR 5 Utilization and Suggests a New Identifies Differences in Glycosylation and C Human Immunodeficiency Virus Type 1 Acute and Chronic Infections with Subtype Comparison of Viral Env Proteins from (2013) (0)
HIV Envelope vaccination elicits asparagine 332 glycan-dependent antibodies that resemble broadly neutralizing antibody precursors (2017) (0)
P20-21 LB. Gene-to-gene differences in evolutionary rate between HIV-1 and natural SIV from sooty mangabeys: implications for vaccine tests in non-human primates (2009) (0)
Structural Topology of Glycoprotein Surface Networks using High Throughput Atomistic Modeling and Graph Theory (2019) (0)
AIDS research pioneer Gerry Myers dies. (2011) (0)
Virus-Specific CTL Responses Coinfection on the Immunodominance of Affinity , Functional Avidity , and Viral Impact of HLA-B Alleles , Epitope Binding Korber (2006) (0)
HIV-1 diversity considerations for clinical studies of passively transferred broadly neutralising antibodies (2019) (0)
Stability and neutralization capacity of a novel mosaic HIV-1 gp140 trimer in a guinea pig model (2012) (0)
Comparison of the depth of vaccine-elicited HIV-1 Env epitope-specific CD8+ T lymphocyte responses (2012) (0)
P03-07. Autologous neutralizing antibodies that select viral escape variants emerge late after SIV infection of rhesus monkeys (2009) (0)
S011-06 OA. HIV specific T cell responses and response patterns associated with viral control independent of classical non-progessor HLA class I alleles (2009) (0)
P16-13. A greater breadth of HIV-1-specific T cell responses detected using mosaic peptides compare to consensus peptides (2009) (0)
P17-09. Immunization with a single HIV-1 envelope sequence can generate CD8+ T lymphocytes capable of recognizing multiple variant forms of envelope (2009) (0)
The D614G mutation in Spike: increased infectivity and neutralizing Ab sensitivity and the underlying mechanism (2020) (0)
Durable Control of HIV-1 Using a Staphylococcus aureus Cas9-Expressing Lentivirus Co-Targeting Viral Latency and Host Susceptibility (2020) (0)
Structural basis for breadth development in a HIV-1 neutralizing antibody (2022) (0)
Improving the reliability of the jpHMM recombination prediction in HIV (2008) (0)
1 Durable Control of HIV-1 Using a Staphylococcus 1 aureus Cas 9-Expressing Lentivirus Co-Targeting 2 Viral Latency and Host Susceptibility 3 (2020) (0)
Envelope Vaccination Shapes Viral Envelope Evolution following Simian Immunodeﬁciency Virus Infection in Rhesus Monkeys (cid:1) (2009) (0)
Epitope-Speciﬁc CD8 (cid:1) T Lymphocytes Cross-Recognize Mutant Simian Immunodeﬁciency Virus (SIV) Sequences but Fail To Contain Very Early Evolution and Eventual Fixation of Epitope Escape Mutations during SIV Infection (cid:1) † (2011) (0)

This paper list is powered by the following services:

Other Resources About Bette Korber

en.wikipedia.org

What Schools Are Affiliated With Bette Korber?

Bette Korber is affiliated with the following schools:

Image Attributions

Image Source for Bette Korber